Liquidia Corporation
LQDA
Clasificación en acciones
#4703
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Precio por acción
$36.07
Capitalización bursátil
$3.23B
Cambio (1 día)
5.68%
Cambio (1 año)
47.59%
País
US
Comercio Liquidia Corporation (LQDA)
Categoría
Healthcare
Ratio P/S de Liquidia Corporation (LQDA)
Ratio P/S al October 2026 TTM: 6.74
Según los informes financieros más recientes y el precio de las acciones de Liquidia Corporation, el ratio P/S actual (TTM) es 6.74. Al final de 2023, el ratio P/S era 44.71.
Historial del ratio P/S de Liquidia Corporation desde 2016 hasta 2026
Ratio P/S al final de cada año
| Año | Ratio P/S | Cambiar |
|---|---|---|
| 2026 (TTM) | 6.74 | -89.81% |
| 2024 | 66.13 | 47.92% |
| 2023 | 44.71 | 83.47% |
| 2022 | 24.37 | 29.46% |
| 2021 | 18.82 | -86.07% |
| 2020 | 135.16 | 1,280.87% |
| 2019 | 9.79 | -82.92% |
| 2018 | 57.32 | 336.47% |
| 2017 | 13.13 | 82.10% |
| 2016 | 7.21 | 0.00% |
Ratio P/S de empresas similares o competidoras
| Empresa | Ratio P/S | Diferencia del ratio P/S | País |
|---|---|---|---|
| 10.31 | 53.04% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 15.12 | 124.46% |
US
|
